GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Baudax Bio Inc (OTCPK:BXRXQ) » Definitions » Cash From Other Investing Activities

Baudax Bio (Baudax Bio) Cash From Other Investing Activities : $0.00 Mil (TTM As of Sep. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Baudax Bio Cash From Other Investing Activities?

Cash from other investing activities means the cash received by a company that comes from other investing activities.

Baudax Bio's cash from other investing activities for the three months ended in Sep. 2023 was $0.00 Mil. It means Baudax Bio received $0.00 Mil from other investing activities. Baudax Bio's cash from other investing activities for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00 Mil.


Baudax Bio Cash From Other Investing Activities Historical Data

The historical data trend for Baudax Bio's Cash From Other Investing Activities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Baudax Bio Cash From Other Investing Activities Chart

Baudax Bio Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash From Other Investing Activities
Get a 7-Day Free Trial - - - - -

Baudax Bio Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cash From Other Investing Activities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Baudax Bio Cash From Other Investing Activities Calculation

Cash from other investing activities means the cash received by a company that comes from other investing activities.

Cash From Other Investing Activities for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Baudax Bio Cash From Other Investing Activities Related Terms

Thank you for viewing the detailed overview of Baudax Bio's Cash From Other Investing Activities provided by GuruFocus.com. Please click on the following links to see related term pages.


Baudax Bio (Baudax Bio) Business Description

Industry
Traded in Other Exchanges
N/A
Address
490 Lapp Road, Malvern, PA, USA, 19355
Baudax Bio Inc is a Pharmaceutical company. The company develops and commercialize products for hospital and related acute care settings. Its products are in pipeline which includes two novel neuromuscular blocking agents, or NMBAs.
Executives
Natalie Mcandrew officer: Interim CFO C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Yong Chan Kim director C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Winston J Churchill director C/O SCP PARTNERS, SUITE 300, 1200 LIBERTY RIDGE DRIVE, WAYNE PA 19087
William Ashton director C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073
Andrew T Drechsler director 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Arnold M Baskies director 1235 SEQUOIA ROAD, CHERRY HILL NJ 08003
Wayne Weisman director 490 LAPP ROAD, MALVERN PA 19355
Jillian Dilmore officer: Corporate Controller/Secretary, other: PFO and PAO C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Geraldine Henwood director, officer: President and CEO 88 SIDNEY ST, CAMBRIDGE MA 02139
Richard S Casten officer: Chief Financial Officer 490 LAPP ROAD, MALVERN PA 19355
Alfred Altomari director C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540
Ryan David Lake director, officer: Chief Financial Officer KENSEY NASH CORPORATION, 735 PENNSYLVANIA DRIVE, EXTON PA 19341
Recro Pharma, Inc. 10 percent owner 1 E. UWCHLAN AVE, SUITE 112, EXTON PA 19341

Baudax Bio (Baudax Bio) Headlines